United StatesHealthcare and life sciences2026 – ongoingRecursion Pharmaceuticals
AI-enabled drug discovery platform for its own pipeline
Recursion said its AI platform delivered advanced drug candidates in about 17 months and about 330 compounds per program
Problem
Early drug discovery usually needs years of chemistry and thousands of synthesized compounds before a candidate is ready for further development.
Approach
Recursion used its own AI-enabled discovery platform across its internal programs. In its full-year 2025 results release it reported the time and compound counts needed to reach advanced candidates. It compared them with industry averages that it cited itself.
Results
Takeaway
Compounds synthesized and months to candidate are measurable discovery outputs. The industry averages are Recursion's own comparison, and the release does not say how they were built.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Recursion's results release states that advanced candidates were delivered by synthesizing about 330 compounds per program in about 17 months, against industry averages of over 2,500 compounds and 42 months. It also says REC-617 was identified as a lead candidate in under 11 months with 136 novel compounds synthesized.
Full details are in the original sources.